BRD3308
SIGMA/SML1639 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 1550053-02-5
Empirical Formula (Hill Notation): C15H14FN3O2
Molecular Weight: 287.29
Linear Formula: C15H14FN3O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C15H14FN3O2/c1-9(20)18 |
| InChI key | RRJDFENBXIEAPD-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | CC(NC1=CC=C(C(NC2=CC=C(F) |
| solubility | DMSO: 10 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3) with an IC50 value of 65 nM for HDAC3 vs. IC50 values of 1.08 μM and 1.15 μM for HDAC1 and HDAC2, respectively. BRD3308 protected pancreatic β cells, suppressing inflammatory cytokine-induced apoptosis and increasing insulin release without the toxicity associated with HDAC1 and HDAC2 inhibitors. In a rat model of type 2 diabetes, BRD3308 reduced hyperglycemia and increased insulin secretion without affecting weight gain. In another study, BRD3308 was found to activate HIV-1 transcription, disrupting HIV-1 latency. |
| Biochem/physiol Actions: | BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3). |
| Biochem/physiol Actions: | BRD3308 promotes outgrowth of HIV-1 (human immunodeficiency virus 1) from inactive infected patient cells. It helps to increase β-cell proliferation. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 |
| Precautionary statements | P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


